期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 68, 期 4, 页码 661-672出版社
SPRINGER
DOI: 10.1007/s00262-018-2264-3
关键词
Myeloid regulatory cells (MRCs); Polymorphonuclear neutrophils; Monocytes; macrophages; Dendritic cells; Tolerance; Mye-EUNITER
资金
- COST (European Cooperation in Science and Technology)
- COST Action [BM1404]
- Scientific and Technical Research Council of Turkey (TUBITAK) [114S354]
- Irish Health Research Board [POR-2013-281]
- Polish National Science Center [2011/02/A/NZ5/00337]
- Ministry of Education, Youth and Sports [LTAUSA17160]
Myeloid cells play a pivotal role in regulating innate and adaptive immune responses. In inflammation, autoimmunity, and after transplantation, myeloid cells have contrasting roles: on the one hand they initiate the immune response, promoting activation and expansion of effector T-cells, and on the other, they counter-regulate inflammation, maintain tissue homeostasis, and promote tolerance. The latter activities are mediated by several myeloid cells including polymorphonuclear neutrophils, macrophages, myeloid-derived suppressor cells, and dendritic cells. Since these cells have been associated with immune suppression and tolerance, they will be further referred to as myeloid regulatory cells (MRCs). In recent years, MRCs have emerged as a therapeutic target or have been regarded as a potential cellular therapeutic product for tolerance induction. However, several open questions must be addressed to enable the therapeutic application of MRCs including: how do they function at the site of inflammation, how to best target these cells to modulate their activities, and how to isolate or to generate pure populations for adoptive cell therapies. In this review, we will give an overview of the current knowledge on MRCs in inflammation, autoimmunity, and transplantation. We will discuss current strategies to target MRCs and to exploit their tolerogenic potential as a cell-based therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据